SCHEMBL6093071

SCHEMBL6093071

CCc1ccc(C=CC(=O)C23CC4CC(CC(C4)C2)C3)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 5/20 0.47
HTT P42858 4/20 0.47
SMN1; SMN2 Q16637 4/20 0.47
MAPT P10636 3/20 0.47
MEN1 O00255 2/20 0.47
KMT2A Q03164 2/20 0.47
ALDH1A1 P00352 2/20 0.47
POLB P06746 1/20 0.47
GAA P10253 1/20 0.47
HDAC3 O15379 3/20 0.47
HDAC1 Q13547 3/20 0.47
HDAC6 Q9UBN7 3/20 0.47
HDAC2 Q92769 2/20 0.47
HDAC5 Q9UQL6 2/20 0.47
HDAC4 P56524 1/20 0.47
HDAC10 Q969S8 1/20 0.47
HDAC8 Q9BY41 1/20 0.47
KDM4E B2RXH2 1/20 0.46
NPC1 O15118 1/20 0.46
RAB9A P51151 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18325433 0.81 ALDH1A1 (0.45) LMNAHTTSMN1; SMN2MAPTMEN1
SCHEMBL6092094 0.81 HSD11B1 (0.51) LMNAHTTSMN1; SMN2MAPTMEN1
SCHEMBL6090902 0.81 CYP1A2 (0.51) LMNAHTTSMN1; SMN2MAPTMEN1
SCHEMBL18317450 0.81 ALDH1A1 (0.45) LMNAHTTSMN1; SMN2MAPTMEN1
SCHEMBL8876584 0.81 HSD11B1 (0.51) LMNAHTTSMN1; SMN2MAPTMEN1
SCHEMBL12040547 0.80 GABBR2 (0.53) LMNAHTTSMN1; SMN2MAPTMEN1
SCHEMBL6091145 0.80 GABBR2 (0.53) LMNAHTTSMN1; SMN2MAPTMEN1
SCHEMBL6093043 0.80 KDM4E (0.54) LMNAHTTSMN1; SMN2MAPTMEN1
SCHEMBL6090666 0.80 HSD17B3 (0.55) LMNAHTTSMN1; SMN2MAPTMEN1
SCHEMBL6093637 0.80 F3 (0.55) LMNAHTTSMN1; SMN2MAPTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060074083-A1 Cyclic and acyclic propenones for treating CNS disorders MERZ PHARMA GMBH & CO. KGAA (DE) 2006-04-06 US claimed
US-20060074083-A1 Cyclic and acyclic propenones for treating CNS disorders MERZ PHARMA GMBH & CO. KGAA (DE) 2006-04-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060074083-A1 Cyclic and acyclic propenones for treating CNS disorders PMP22, ADCYAP1R1, CYP11B2 LMNA 2359/4885HTT 244/4885SMN1; SMN2 323/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.